אומר-יג-אם % 5
omrix biopharmaceuticals - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 50 mg/ml mg/ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy * primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinemia or hypogammaglobulinemia) * myeloma or chronic lymphocytic leukemia (cll) with severe secondary hypogammaglobulinemia and recurrent infections. * children with congenital aids and recurrent infections - immunomodulation * idiopathic thrombocytopenic purpura (itp) * guillain barre syndrome * kawasaki disease - allogenic bone marrow transplantation
אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 50 מ"ג
novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.
אוקסליפלטין הוספירה 5 מ"ג/מ"ל - 100 מ"ג
novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.
אוקסליפלטין הוספירה 5 מ"ג/מ"ל
novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.
אירינוטקאן זריקות 20 מ"ג/מ"ל
novapharma ltd - irinotecan (trihydrate) hydrochloride 20 mg/ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.
לוקרין פ.ד.ס דפו 11.25 מג
abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin
לוקרין פ.ד.ס דפו 11.25 מג
abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 11.25 mg - leuprorelin
לוקרין פ.ד.ס דפו 3.75 מג
abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 3.75 mg - leuprorelin
לוקרין פ.ד.ס דפו 3.75 מג
abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - leuprorelin acetate 3.75 mg - leuprorelin
ונקלקסטה 10 מג טבליות
abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 10 mg - venetoclax